Developing a targeted delivery system for Leuconostoc mesenteroides in IBD treatment
Developing a targeted delivery system for Leuconostoc mesenteroides in IBD treatment
Masoud Zandi,1,*
1. Department of Nursing, Tuyserkan Branch, Islamic Azad University, Tuyserkan, Iran
Introduction: Inflammatory bowel disease (IBD) includes various inflammatory disorders of the intestine, associated with imbalances in gut microbiota. Bacteriotherapy shows promise in treating IBD by correcting gut dysbiosis and reducing inflammatory mediators. Probiotics such as Leuconostoc mesenteroides (NRRL B-1118), when administered orally, can produce beneficial substances, inhibit pathogen growth, and help restore the balance of gut microbiota. However, environmental challenges in the gastrointestinal (GI) tract, such as gastric acids, significantly reduce the viability and activity of probiotics after oral intake. Inadequate mucoadhesive properties of probiotics result in reduced colonization efficiency and therapeutic impacts.To address these issues, coating probiotics with functional biomaterials can protect them and extend their retention time in the GI tract.
Methods: In this study, we developed a targeted delivery system using a double-layer electrostatic assembly method to encapsulate L. mesenteroides in layers of mucoadhesive chitosan (CS) and hyaluronic acid (HA), creating HA-CS-L. mesenteroides. These protective layers provide the encapsulated L. mesenteroides with enhanced resistance to environmental stresses and improved mucoadhesion in the GI tract.
Results: As a result, the probiotics can more effectively suppress inflammation and modify the intestinal environment, improving their therapeutic efficacy for IBD prevention and treatment.
Conclusion: This study introduces an innovative probiotic coating strategy enhancing the effectiveness of bacteriotherapy in combating IBD.